Galunisertib (LY2157299), an orally administered small molecule that inhibits TGFβRI kinase and TGF‐β, was extensively evaluated on various NSCLC or SCLC tumor models (either patient‐derived xenografts or cell line‐derived xenografts) [253]. The gene discussed is TGFB1; the disease is neoplasm.